Similarly, in a smaller trial of romidepsin plus tenalisib (an inhibitor of PI3K-γδ and salt-inducible kinase 3 [SIK3]), high response rates were observed in PTCL (75% ORR) and CTCL (35% ORR) [41]. The gene discussed is SIK3; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.